Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors

P. Kongtim, K. Adekola, D. R. Milton, R. Ramlal, A. Jimenez, J. Chen, G. Rondon, S. Ahmed, P. Kebriaei, O. Betul, C. M. Hosing, U. Popat, I. Khouri, E. Jabbour, J. E. Cortes, H. M. Kantarjian, R. E. Champlin, S. O. Ciurea

Research output: Contribution to journalLetter

4 Scopus citations
Original languageEnglish (US)
Pages (from-to)1654-1657
Number of pages4
JournalLeukemia
Volume31
Issue number7
DOIs
StatePublished - Jul 1 2017
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Kongtim, P., Adekola, K., Milton, D. R., Ramlal, R., Jimenez, A., Chen, J., Rondon, G., Ahmed, S., Kebriaei, P., Betul, O., Hosing, C. M., Popat, U., Khouri, I., Jabbour, E., Cortes, J. E., Kantarjian, H. M., Champlin, R. E., & Ciurea, S. O. (2017). Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Leukemia, 31(7), 1654-1657. https://doi.org/10.1038/leu.2017.118